315 related articles for article (PubMed ID: 18297609)
1. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609
[TBL] [Abstract][Full Text] [Related]
2. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.
Padurariu M; Ciobica A; Hritcu L; Stoica B; Bild W; Stefanescu C
Neurosci Lett; 2010 Jan; 469(1):6-10. PubMed ID: 19914330
[TBL] [Abstract][Full Text] [Related]
3. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
Hernanz A; De la Fuente M; Navarro M; Frank A
Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
[TBL] [Abstract][Full Text] [Related]
4. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
5. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
Galimberti D; Fenoglio C; Lovati C; Venturelli E; Guidi I; Corrà B; Scalabrini D; Clerici F; Mariani C; Bresolin N; Scarpini E
Neurobiol Aging; 2006 Dec; 27(12):1763-8. PubMed ID: 16307829
[TBL] [Abstract][Full Text] [Related]
6. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Immunol Lett; 2008 May; 117(2):198-202. PubMed ID: 18367253
[TBL] [Abstract][Full Text] [Related]
7. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease.
Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU
Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084
[TBL] [Abstract][Full Text] [Related]
8. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F; Poljak A; Smythe GA; Sachdev P
Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319
[TBL] [Abstract][Full Text] [Related]
9. Oxidative damage in mild cognitive impairment and early Alzheimer's disease.
Lovell MA; Markesbery WR
J Neurosci Res; 2007 Nov; 85(14):3036-40. PubMed ID: 17510979
[TBL] [Abstract][Full Text] [Related]
10. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease.
Guidi I; Galimberti D; Lonati S; Novembrino C; Bamonti F; Tiriticco M; Fenoglio C; Venturelli E; Baron P; Bresolin N; Scarpini E
Neurobiol Aging; 2006 Feb; 27(2):262-9. PubMed ID: 16399211
[TBL] [Abstract][Full Text] [Related]
11. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study.
Luckhaus C; Grass-Kapanke B; Blaeser I; Ihl R; Supprian T; Winterer G; Zielasek J; Brinkmeyer J
Int J Geriatr Psychiatry; 2008 Nov; 23(11):1148-55. PubMed ID: 18537220
[TBL] [Abstract][Full Text] [Related]
12. Oxidative inactivation of the proteasome in Alzheimer's disease.
Cecarini V; Ding Q; Keller JN
Free Radic Res; 2007 Jun; 41(6):673-80. PubMed ID: 17516240
[TBL] [Abstract][Full Text] [Related]
13. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.
Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C
Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
Buchhave P; Janciauskiene S; Zetterberg H; Blennow K; Minthon L; Hansson O
Neurosci Lett; 2009 Jan; 450(1):56-9. PubMed ID: 18996438
[TBL] [Abstract][Full Text] [Related]
16. Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment.
Ghidoni R; Benussi L; Glionna M; Desenzani S; Albertini V; Levy E; Emanuele E; Binetti G
J Alzheimers Dis; 2010; 22(3):985-91. PubMed ID: 20858959
[TBL] [Abstract][Full Text] [Related]
17. Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease.
Kharrazi H; Vaisi-Raygani A; Rahimi Z; Tavilani H; Aminian M; Pourmotabbed T
Clin Biochem; 2008 Aug; 41(12):932-6. PubMed ID: 18505684
[TBL] [Abstract][Full Text] [Related]
18. QT dispersion and heart rate variability abnormalities in Alzheimer's disease and in mild cognitive impairment.
Zulli R; Nicosia F; Borroni B; Agosti C; Prometti P; Donati P; De Vecchi M; Romanelli G; Grassi V; Padovani A
J Am Geriatr Soc; 2005 Dec; 53(12):2135-9. PubMed ID: 16398898
[TBL] [Abstract][Full Text] [Related]
19. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease.
Lanni C; Racchi M; Stanga S; Mazzini G; Ranzenigo A; Polotti R; Memo M; Govoni S; Uberti D
J Alzheimers Dis; 2010; 20(1):97-104. PubMed ID: 20164600
[TBL] [Abstract][Full Text] [Related]
20. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease.
Torres LL; Quaglio NB; de Souza GT; Garcia RT; Dati LM; Moreira WL; Loureiro AP; de Souza-Talarico JN; Smid J; Porto CS; Bottino CM; Nitrini R; Barros SB; Camarini R; Marcourakis T
J Alzheimers Dis; 2011; 26(1):59-68. PubMed ID: 21593563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
